The prognosis of retroperitoneal sarcoma can be determined by serum markers of the innate inflammatory response [e.g., neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP)] (26). The gene discussed is CRP; the disease is retroperitoneal sarcoma.